C O N F I R M E D : Y O U R S P O T I S R E S E R V E D
Join Dylan Jovine’s Biotech Insider
For $1,000 OFF
The Retail Price…
And Receive His Latest Report, The Buyout Window: 3 Tiny Stocks Poised For 6am Windfalls Free
100 Responders
Congratulations.
You’ve made a smart decision to join Biotech Insider today...
Because like Dylan just showed you…
One buyout announcement can pay you years of stock market gains in a single morning.
That’s not a figure of speech.
When Pfizer moved on Array BioPharma, shares closed up 148% — in a single trading day.
When AbbVie moved on ImmunoGen, the stock jumped 83% on the announcement, and my readers got to book a 449% total gain.
And when Vertex acquired Crinetics Pharmaceuticals this year, shares popped 101% in a single day.
That’s the entire point of Biotech Insider.
To get you into the tiny biotech firms that Big Pharma is virtually FORCED to buy…
And Right Now, Three Forces Are About To Open The Biggest Buyout Window in Biotech History
Force #1: The Biggest Patent Cliff in Biotech History
Over the next four years, drugs generating more than $300 billion a year in revenue lose patent protection…
Including Keytruda - the best-selling drug on earth at nearly $30 billion a year.
Merck isn't alone. An entire generation of blockbusters rolls off in the same window.
Big Pharma can't invent replacements fast enough.
So they are FORCED to buy tiny biotechs to replenish their drug pipelines...
Force #2: The Biggest War Chest Ever Assembled.
Big Pharma is sitting on $1.3 trillion in dealmaking firepower, according to Ernst & Young.
Across life sciences, it's a record $2.1 trillion…
The biggest war chest in biotech history.
Force #3: The Greatest Buyer’s Market in Biotech History
Through last year, roughly a third of every listed biotech firm in America was trading under its cash value.
That’s like somebody offering you a $100 bill for $90.
For investors, it’s a dream come true.
It gives YOU a chance to buy these firms at rock-bottom valuations…
And it makes them the perfect acquisition target for Big Pharma’s buying spree.
Together, these three forces could open up the biggest buyout window in biotech history…
A historic spree of takeovers that could mint an entire new class of millionaires.
And with Dylan’s top biotech recommendations you’re perfectly positioned to profit.
But there’s not much time left to get in...
The Buyout Spree Has Already Started
Merck just bought Terns Pharmaceuticals for $6.7 billion.
Pfizer just acquired Metsera for $10 billion.
Boston Scientific just took over Penumbra for $14.5 billion.
Altogether, 37 biotech buyouts valued over $1 billion have closed this year.
An all-time record, with deal volume nearly double last year.
The Financial Times reports big pharma groups are snapping up biotechs at a record pace.
And when the call comes, these stocks reprice instantly:
- Allergan acquired Tobira Therapeutics, and shares exploded as much as 700% in a single day
- Pfizer bought Trillium Therapeutics, and shares jumped 188% in a single day
- Merck took over VelosBio for its oncology pipeline, and shares soared 160% in a single day
This could be your last chance to get positioned before the window blows open.
Here Is Everything You Receive Immediately:
When you agree to test-drive Biotech Insider today, you will get full access to Dylan's model portfolio and four proprietary biotech briefings.
A FULL YEAR OF
Biotech Insider
$2,997 Value
Every new pick Dylan uncovers. Every new takeover target he's tracking. And his sell alerts, so you know exactly when to lock in your gains and walk away a winner.
A few of the winners already in the book:
- 449% on ImmunoGen when AbbVie bought it out
- 300% on ChemoCentryx before Amgen swept it up
- 242% on Krystal Biotech
- 190% on Viking Therapeutics
- 151% on Eli Lilly
Since Dylan launched Biotech Insider in 2018, the average closed trade has returned 35.5%. Winners and losers combined.
And during the last buyout window, he did even better.
Every position closed in 2023 and 2024 averaged a 52.9% gain per trade. Again, winners and losers.
Across those same two years, the broader biotech sector delivered just 8.7%.
That's over 6X the entire sector. During what Wall Street called a “biotech winter.”
Bonus Report #1
The Buyout Window
3 Tiny Stocks Poised For 6am Windfalls
$1,997 Value
All three picks. Names, ticker symbols, and exactly how to position in each.
The Keytruda Killer. In a Phase 3 lung cancer trial, this firm’s therapy went toe to toe with Keytruda and came out so far ahead that roughly $6 billion in Merck market value got wiped out almost instantly. Nature.com called it the first direct challenge to Merck’s behemoth. Merck has already spent about $29 billion buying biotechs to prepare for the cliff. And Dylan believes it will snap up this tiny firm next. You can still scoop up shares for $15.
Dylan’s #1 Biotech Takeover Target. A tiny oncology firm, and the first ever to bring a new type of blood cancer drug to market. Not trial results. Full FDA approval, on the market now, with revenue ramping. One of Japan’s biggest drugmakers committed $1.5 billion to it - more than this entire firm is worth. And Dylan believes a full takeover is only a matter of time.
The Company Biogen Already Bought Half Of. This is a stake in the one thing Big Pharma has chased for fifty years: a delivery system that carries medicine across the blood-brain barrier and into the brain. The FDA already approved the first drug it delivered, the first product ever approved to address the neurologic complications of Hunter syndrome. Biogen has already taken a 50/50 stake in this firm’s Parkinson's program. But Biogen only owns half of one drug. It doesn't own the platform. And there's exactly one way to get that. Shares are still around $22.
Dylan recommends you take a position in all three right away.
Bonus Report #2
The New American Titan
$500 Value
On December 18, 2025, Trump signed the BIOSECURE Act, creating a blacklist of Chinese pharmaceutical suppliers. Source your ingredients from them and you risk federal contracts, grants and Medicare reimbursements. The problem: 79% of U.S. drugmakers rely on Chinese suppliers, and one blacklisted firm touches one in four drugs Americans take.
Inside is the American supplier Dylan believes is first in line to fill that gap. It produces ultra-pure chemicals, single-use bioprocessing assemblies and medical-grade filtration to over 300,000 customer locations across 180 countries. Fourteen drugmakers have committed $480 billion to build American factories, and every one of them needs what this company sells.
Shares trade under $12. A director just bought 50,000 of them on the open market.
Bonus Report #3
The End of Disease
The AI Company Revolutionizing Medicine
$500 Value
There are 10,000 known diseases and only about 500 cures. The reason is math: the average drug takes 12 years and $2.6 billion to bring to market, so companies chase one disease at a time. This report shows you the technology that collapses that timeline from years to days, and names the small companies whose software Pfizer, Merck, AstraZeneca and Eli Lilly already run on.
It's the difference between waiting for the next cure and owning the machine that makes them. You'll have it in your first ten minutes as a member.
Bonus Report #4
The FDA Catalyst Calendar
Q3 2026
$500 Value
Real dates, real companies, a calendar of the biotech catalysts scheduled to hit in the weeks ahead. The exact moments these stocks move fastest. While everyone else reacts to the news, you’ll be looking at the calendar before it happens. Your radar for the entire buyout window.
MONEYBACK GUARANTEE
Keep Everything,
Risk Nothing Guarantee
Join today and you get a full 30 days to go through everything.
Read all four reports. Look at every recommendation. Follow Dylan’s alerts.
If you decide Biotech Insider isn’t everything he promised and more…
Just call our team inside those 30 days.
You’ll get a full refund of your membership fee.
And you keep every report you’ve downloaded. They’re yours either way.
⚠️ But you do have to decide now.
The money is already moving. Biotech is up about 29% this year against roughly 10% for the S&P 500.
Biotech IPOs have trounced every other sector on the board, posting a standout 55% return and crushing AI listings.
AbiVax has soared over 1,200% in recent months.
And if you wait even one day, you may be reading about the gain instead of collecting it.
Here’s What Dylan’s Readers Have To Say About Biotech Insider
- “That was the fastest $19,275 I have ever made in my life. You recommended Loxo Friday morning and it was taken over Monday. Wow.” — Scott S., Pasadena, California
- “One stock I owned, Loxo, soared 90% in 3 days giving me an insane profit.” — Mike K., Boonton, New Jersey
- “Tesaro was a great tip. I made incredible gains in 3 weeks from it.” — Karen, Ashland, Kentucky
CLAIM YOUR VIP UNLIMITED SUBSCRIPTION DISCOUNT
The standard retail price for a one-year membership to Biotech Insider is $6,494. And based on the verified, documented historical performance of Dylan's recommendations, that is an absolute bargain.
For the first 100 people who respond to this page:
You will pay just $1,997 for the full year.
That is roughly $5.47 a day. Less than the cost of a latte.
⚠ WARNING: But remember, Big Pharma has already started its historic acquisition spree. You don't want to miss out on the biggest buyout window this market has ever seen. We cannot guarantee this entry price will last beyond today.
Complete the secure form below to activate your membership and instantly download your reports.
Activate Your Subscription
Order Summary:
